Ultrasound-guided Therapeutic Modulation of Hepatocellular Carcinoma Using Complementary MicroRNAs

Overview

Journal J Control Release

Specialty Pharmacology

Date 2016 Aug 10

PMID 27503707

Citations 38

Authors

Sayan Mullick Chowdhury

Tzu-Yin Wang

Sunitha Bachawal

Rammohan Devulapally

Jung Woo Choe

Lotfi Abou Elkacem

Butrus Khuri Yakub

David S Wang

Lu Tian

Ramasamy Paulmurugan

Jurgen K Willmann

Affiliations

Soon will be listed here.

Abstract

Treatment options for patients with hepatocellular carcinoma (HCC) are limited, in particular in advanced and drug resistant HCC. MicroRNAs (miRNA) are non-coding small RNAs that are emerging as novel drugs for the treatment of cancer. The aim of this study was to assess treatment effects of two complementary miRNAs (sense miRNA-122, and antisense antimiR-21) encapsulated in biodegradable poly (lactic-co-glycolic acid) nanoparticles (PLGA-NP), administered by an ultrasound-guided and microbubble-enhanced delivery approach in doxorubicin-resistant and non-resistant human HCC xenografts. Proliferation and invasiveness of human HCC cells after miRNA-122/antimiR-21 and doxorubicin treatment were assessed in vitro. Confocal microscopy and qRT-PCR were used to visualize and quantitate successful intracellular miRNA-loaded PLGA-NP delivery. Up and down-regulation of miRNA downstream targets and multidrug resistance proteins and extent of apoptosis were assessed in vivo in treated human HCC xenografts in mice. Compared to single miRNA therapy, combination therapy with the two complementary miRNAs resulted in significantly (P<0.05) stronger decrease in cell proliferation, invasion, and migration of HCC cells as well as higher resensitization to doxorubicin. Ultrasound-guided delivery significantly increased in vivo miRNA-loaded PLGA-NP delivery in human HCC xenografts compared to control conditions by 5-9 fold (P<0.001). miRNA-loaded PLGA-NP were internalized in HCC cells and anti-apoptotic proteins were down regulated with apoptosis in ~27% of the tumor volume of doxorubicin-resistant human HCC after a single treatment with complementary miRNAs and doxorubicin. Thus, ultrasound-guided delivery of complementary miRNAs is highly efficient in the treatment of doxorubicin- resistant and non-resistant HCC. Further development of this new treatment approach could aid in better treatment of patients with HCC.

Citing Articles

Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.

Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E Heliyon. 2024; 10(20):e39489.

PMID: 39498055 PMC: 11532857. DOI: 10.1016/j.heliyon.2024.e39489.

Engineering Versatile Nanomedicines for Ultrasonic Tumor Immunotherapy.

Liang J, Qiao X, Qiu L, Xu H, Xiang H, Ding H Adv Sci (Weinh). 2023; 11(3):e2305392.

PMID: 38041509 PMC: 10797440. DOI: 10.1002/advs.202305392.

Diameter-dependent assessment of microvascular leakage following ultrasound-mediated blood-brain barrier opening.

Katz S, Gattegno R, Peko L, Zarik R, Hagani Y, Ilovitsh T iScience. 2023; 26(6):106965.

PMID: 37378309 PMC: 10291464. DOI: 10.1016/j.isci.2023.106965.

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors.

Wu Q, Xia Y, Xiong X, Duan X, Pang X, Zhang F Front Pharmacol. 2023; 14:1169608.

PMID: 37180717 PMC: 10173311. DOI: 10.3389/fphar.2023.1169608.

The role of acoustofluidics and microbubble dynamics for therapeutic applications and drug delivery.

Kaykanat S, Uguz A Biomicrofluidics. 2023; 17(2):021502.

PMID: 37153864 PMC: 10162024. DOI: 10.1063/5.0130769.

References

Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z . MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer. 2013; 13:469. PMC: 3852118. DOI: 10.1186/1471-2407-13-469. View

Panje C, Wang D, Pysz M, Paulmurugan R, Ren Y, Tranquart F . Ultrasound-mediated gene delivery with cationic versus neutral microbubbles: effect of DNA and microbubble dose on in vivo transfection efficiency. Theranostics. 2012; 2(11):1078-91. PMC: 3516840. DOI: 10.7150/thno.4240. View

Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L . miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep. 2012; 27(5):1660-8. DOI: 10.3892/or.2012.1682. View

Boado R, Pardridge W . Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system. Bioconjug Chem. 1992; 3(6):519-23. DOI: 10.1021/bc00018a010. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

Raoul J, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L . Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2010; 37(3):212-20. DOI: 10.1016/j.ctrv.2010.07.006. View

Dong Z, Ren L, Lin L, Li J, Huang Y, Li J . Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. Mol Med Rep. 2014; 11(1):682-90. DOI: 10.3892/mmr.2014.2662. View

Smith L, Watson M, OKane S, Drew P, Lind M, Cawkwell L . The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 2006; 5(8):2115-20. DOI: 10.1158/1535-7163.MCT-06-0190. View

Shibata C, Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A . Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol Cell Ther. 2015; 1:5. PMC: 4448951. View

10.

Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View

11.

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012; 48(5):599-641. DOI: 10.1016/j.ejca.2011.12.021. View

12.

Devulapally R, Sekar N, Sekar T, Foygel K, Massoud T, Willmann J . Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano. 2015; 9(3):2290-302. PMC: 4374409. DOI: 10.1021/nn507465d. View

13.

Lang Q, Ling C . MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun. 2012; 426(2):247-52. DOI: 10.1016/j.bbrc.2012.08.075. View

14.

Panje C, Wang D, Willmann J . Ultrasound and microbubble-mediated gene delivery in cancer: progress and perspectives. Invest Radiol. 2013; 48(11):755-69. DOI: 10.1097/RLI.0b013e3182982cc1. View

15.

Hsu S, Yu B, Wang X, Lu Y, Schmidt C, Lee R . Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine. 2013; 9(8):1169-80. PMC: 3815988. DOI: 10.1016/j.nano.2013.05.007. View

16.

Sarkar F, Li Y, Wang Z, Kong D, Ali S . Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010; 13(3):57-66. PMC: 2883024. DOI: 10.1016/j.drup.2010.02.001. View

17.

Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W . Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006; 99(3):671-8. PMC: 3033198. DOI: 10.1002/jcb.20982. View

18.

Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F . Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011; 6:877-95. PMC: 3124394. DOI: 10.2147/IJN.S18905. View

19.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

20.

Giglia J, Antonia S, Berk L, Bruno S, Dessureault S, Finkelstein S . Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control. 2010; 17(2):120-9. DOI: 10.1177/107327481001700207. View